Healthcare, Pharma & Life Sciences

J&J's CARVYKTI Shows 50% Five-Year Remission Rate in Early-Line Myeloma

Image
J&J's CARVYKTI Shows 50% Five-Year Remission Rate in Early-Line Myeloma

Raritan, N.J. – September 25, 2026 -- Half of patients with early-line relapsed or refractory multiple myeloma treated with a single infusion of Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) remained alive and progression-free for at least five years without maintenance therapy, according to new long-term data from the Phase 2 CARTITUDE-2 study.

Half of patients reach five-year progression-free survival without maintenance

In the initial subgroup of cohort A (N=20), 10 of 20 patients treated with a single CARVYKTI® infusion remained progression-free at a median follow-up of 60.7 months. Median progression-free survival reached 60.5 months, and the results were presented at the International Myeloma Society Annual Meeting (Abstract #PA-288). Cohort A enrolled patients who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide.

Sterling Contract Packaging Featured on Public TV for Integrated Healthcare Packaging Model

Image
Sterling Contract Packaging Featured on Public TV for Integrated Healthcare Packaging Model

South Carolina -- A new Public Television segment filmed on September 25, 2026, at Sterling Contract Packaging's South Carolina facility examines how consolidating packaging design, engineering, and manufacturing under one operator is reshaping healthcare product distribution. The feature, part of the nationally syndicated "All Access hosted by Andy Garcia" series, positions single-source packaging models as an alternative to fragmented, multi-vendor supply chains that have historically caused delays and compliance failures in the medical device and OTC pharmaceutical sectors.

Lundbeck Moves US HQ From Deerfield to Greater Boston

Copenhagen – September 25, 2026 -- H. Lundbeck A/S will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, establishing a global innovation hub in the region over the next year.

Lundbeck ties the move to the next phase of its Focused Innovator strategy

The Danish biopharmaceutical company said the relocation supports plans to scale its growing neuroscience portfolio, expand innovation opportunities and build out digital and AI capabilities. Charl van Zyl, President and CEO of Lundbeck, said the US has been a key driver of the company's commercial progress over the past three years, during which Lundbeck delivered growth, transformed its pipeline and applied disciplined capital allocation.

SciBase Rights Issue Fully Covered as Bergs Securities Confirms SEK 24.2M Guarantee

Stockholm – September 25, 2026 -- SciBase Holding AB's SEK 57.5 million rights issue is now fully covered after Bergs Securities AB confirmed a binding guarantee commitment of approximately SEK 24.2 million, equal to 42 percent of the offering.

Guarantee commitment converts letter of intent into binding coverage

Bergs Securities fulfilled on September 25, 2026, a guarantee intention it first announced on September 3, 2026, by delivering a formal guarantee confirmation to SciBase. The firm has backed the commitment with sub-guarantee agreements from a consortium of investors covering the full guaranteed amount.

XtalPi Files FDA IND for First Gut-Restricted Pan-TRK Pain Drug

Image
XtalPi Files FDA IND for First Gut-Restricted Pan-TRK Pain Drug

Boston and Shenzhen – September 25, 2026 -- XtalPi Holdings Limited (HKEX: 2228) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for KQTD-126, a potential first-in-class gut-restricted pan-tropomyosin receptor kinase (pan-TRK) inhibitor targeting chronic intestinal pain in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

KQTD-126 marks XtalPi's first proprietary pipeline candidate to reach IND stage

The submission represents the inaugural IND filing from XtalPi's internally developed pipeline, which the company disclosed in its recent interim results. It confirms the company's transition from a discovery-services provider to a clinical-stage drug developer built on AI and robotics.

REGENXBIO: 60% of Sura-Vec Patients Show DRSS Gains at 3 Years

Image
REGENXBIO: 60% of Sura-Vec Patients Show DRSS Gains at 3 Years

Rockville, Md. – September 25, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

Three-year data confirm durable DRSS improvement without repeat injections

In long-term follow-up as of September 25, 2026, six of ten Dose Level 3 participants with non-proliferative diabetic retinopathy (NPDR) who reached the three-year visit sustained a greater-than-2-step DRSS improvement without additional diabetic retinopathy treatment. The suprachoroidal delivery used Dose Level 3 (1.0x10^12 GC/eye) combined with short-course prophylactic topical steroids.

Autoimmune Treatment Market to Nearly Double to $321.95B by 2034

Image
Autoimmune Treatment Market to Nearly Double to $321.95B by 2034

Pune – September 25, 2026 -- The global autoimmune treatment market reached USD 176.6 billion in 2025 and is forecast to expand at a 6.9% CAGR through 2034, hitting USD 321.95 billion, according to a new analysis from Maximize Market Research.

North America dominates the market on strong pharmaceutical R&D infrastructure

North America held the largest share of the market in 2025, driven by high disease prevalence, advanced healthcare infrastructure, established specialist care and elevated healthcare spending. The United States anchors regional growth, backed by leading pharmaceutical and biotechnology firms, advanced diagnostic capacity, and rising adoption of biologics, immunosuppressants, monoclonal antibodies and targeted therapies. Canada and Mexico are contributing through improving healthcare access and disease awareness.

Nanomedicine Market to Nearly Triple to $581.2B by 2034

Image
Nanomedicine Market to Nearly Triple to $581.2B by 2034

Pune, India – September 25, 2026 -- The global nanomedicine market reached USD 207.91 billion in 2025 and is projected to hit USD 581.2 billion by 2034, expanding at a 12.1% compound annual growth rate, according to a new report from Maximize Market Research.

North America commands the largest share on pharmaceutical R&D strength

North America held the largest share of the market in 2025, driven by advanced healthcare infrastructure, deep pharmaceutical and biotechnology research pipelines, and high healthcare expenditure. The United States anchors regional growth through its established research ecosystem and rising adoption of nanotechnology-based drug delivery, diagnostics and precision medicine platforms. Canada and Mexico are contributing through expanding healthcare capabilities and research initiatives.

MS Treatment Market to Hit $44.45B by 2034 on DMT Demand

Image
MS Treatment Market to Hit $44.45B by 2034 on DMT Demand

Pune, India – September 25, 2026 -- The global multiple sclerosis treatment market reached USD 26.76 billion in 2025 and is forecast to climb to USD 44.45 billion by 2034, expanding at a 5.8% CAGR, according to a new report from Maximize Market Research.

Disease-modifying therapies and biologics drive current market expansion

Rising MS prevalence, improved diagnostic capabilities, and growing adoption of immunomodulators, immunosuppressants, interferons, oral disease-modifying therapies (DMTs), and monoclonal antibodies are fueling demand across relapsing-remitting (RRMS), primary progressive (PPMS), secondary progressive (SPMS), and clinically isolated syndrome (CIS) patient segments. High-efficacy biologics and oral treatment options are increasingly displacing older therapy classes as patients and physicians prioritize convenience and disease-progression control.

Placenta Market to Hit $275 Billion by 2034 on Cosmetics Boom

Image
Placenta Market to Hit $275 Billion by 2034 on Cosmetics Boom

Pune, India – September 25, 2026 -- The global placenta market is set to nearly triple from USD 96.1 billion in 2025 to USD 275.18 billion by 2034, expanding at a 12.4% compound annual growth rate, according to a new analysis by Maximize Market Research.

Asia-Pacific leads global demand as Japan, South Korea and China drive placenta research

Asia-Pacific held the leading market position in 2025, backed by strong placenta research and development in Japan, South Korea and China, alongside rising production of placenta-derived products for pharmaceutical and cosmetics applications. The region's large consumer base and appetite for anti-aging and skincare solutions continue to underpin its dominant position.